Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer.

Publication date: Jan 07, 2020

Genomically-guided clinical trials are performed across different tumor types sharing genetic mutations, but trial organization remains complex. Here we address the feasibility and utility of routine somatic and constitutional exome analysis in metastatic cancer patients.

Exoma trial (NCT02840604) is a multicenter, prospective clinical trial. Eligible patients presented a metastatic cancer progressing after at least one line of systemic therapy. Constitutional genetics testing required geneticist consultation. Somatic and germline exome analysis was restricted to 317 genes. Variants were classified and molecular tumor board made therapeutic recommendations based on ESMO guidelines. Primary endpoint was the feasibility of the approach evaluated by the proportion of patient that received a therapeutic proposal.

Between May 2016 and October 2018, 506 patients were included. Median time required for tumor sample reception was 8 days. Median time from sample reception to results was 52 days. Somatic analysis was performed for 456 patients (90.1%). Both somatic and constitutional analyses were successfully performed for 386 patients (76.3%). In total, 342 patients (75%) received a therapeutic proposal. Genetic susceptibility to cancer was found in 35 (9%) patients. Only, 79 patients (23.1%) were treated with NGS matched therapy mainly PI3K/AKT/mTOR inhibitors 22 (27.8%), followed by PARP inhibitors 19 (24.1%), antiangiogenics 17 (21.5%), MEK inhibitors 7 (8.9%) and immunotherapy 5 (6.3%). Matched treatment was finally stopped because of disease progression 50 (63%), treatment toxicity 18 (23%), patients’ death 4 (5%). PFS2/PFS1 ratio was > 1,3 for 23,5% of patients treated with the NGS matched therapy and 23,7% of patients treated with standard therapy.

Study shows that exome analysis is feasible in cancer routine care. This strategy improves detection of genetic predispositions and enhances access to target therapies. However, no differences were observed between PFS ratios of patients treated with matched therapy versus standard therapy.

This work was funding by the centre Georges Francois Leclerc.

Open Access PDF

R’eda, M., Richard, C., Bertaut, A., Niogret, J., Collot, T., Fumet, J.D., Blanc, J., Truntzer, C., , Desmoulins, Ladoire, S., Hennequin, A., Favier, L., Bengrine, L., Vincent, J., Hervieu, A., Dusserre, J.G., Lepage, C., Foucher, P., Borg, C., Albuisson, J., Arnould, L., Nambot, S., Faivre, L., Boidot, R., and Ghiringhelli, F. Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer. 06143. 2020 EBioMedicine (51):

Concepts Keywords
AKT Exome sequencing
Cancer DNA sequencing
Clinical Trial Applied genetics
Clinical Trials Molecular biology
Exome Branches of biology
Genetic Immunotherapy
Genetic Mutations Molecular tumor
Geneticist PARP inhibitor
Germline Personalized onco-genomics
Systemic Therapy


Type Source Name
disease MESH cancer
disease MESH disease progression
disease MESH death
drug DRUGBANK Coenzyme M
disease MESH Pathology
disease MESH Anomalies
disease MESH syndromes
disease MESH melanoma
pathway KEGG Melanoma
drug DRUGBANK Diethylstilbestrol
drug DRUGBANK Ademetionine
disease MESH metastasis
drug DRUGBANK Methyl isocyanate
disease MESH Adenocarcinoma
disease MESH carcinoma
disease MESH classi
drug DRUGBANK Methionine
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH ovarian cancer
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH pancreatic cancer
pathway KEGG Pancreatic cancer
drug DRUGBANK Hexocyclium
drug DRUGBANK Myricetin
drug DRUGBANK Vorinostat
drug DRUGBANK Trestolone
drug DRUGBANK Nitrogen trichloride
drug DRUGBANK Formaldehyde
disease MESH multiple
drug DRUGBANK Indoleacetic acid
disease MESH lung cancer
disease MESH small cell lung cancer
pathway KEGG Small cell lung cancer
disease MESH diagnosis
drug DRUGBANK Cefalotin
drug DRUGBANK Guanosine


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *